Dr Michael Winlo recently spoke with Steve Jones at Cannabiz following the announcement that Emyria has received ethics approval for Phase 3 clinical trials of EMD-RX5.

The trial is another step toward registration of EMD-RX5 with the Therapeutic Goods Administration as an over-the-counter treatment for psychological distress, and as Dr Winlo discusses, it is only by taking steps toward registration that the potential of medical cannabis can be unleashed.

Read the article here (behind paywall):
Cannabis risks becoming a ‘borderline supplement’ unless it evolves, warns Emyria chief | Cannabiz